Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | HTR2B | P41595 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681560 | 0.82 | HTR2C (0.36) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL31159776 | 0.79 | KDM4E (0.41) | MEN1KMT2ACTDSP1KDM4EGAA | |
| SCHEMBL2062317 | 0.77 | MEN1 (0.36) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL1681204 | 0.77 | MEN1 (0.32) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL8533282 | 0.77 | HTR2C (0.40) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL391888 | 0.77 | S1PR4 (0.39) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2062255 | 0.76 | CYP3A4 (0.40) | ADRA2AADRA2BADRA2CMEN1KMT2A | |
| SCHEMBL1681101 | 0.75 | MAP2K1 (0.41) | — | |
| SCHEMBL1681083 | 0.75 | MAP2K1 (0.39) | MEN1KMT2A | |
| SCHEMBL11909148 | 0.75 | PKM (0.42) | MEN1KMT2ACTDSP1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2488507-B1 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2488507-B1 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2488507-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | Allostem Therapeutics LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2011047055-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047055-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | MYLK2, MAPK1, MAP3K1 | HTR2C 4702/4885HTR2B 4545/4885HTR2A 4337/4885 |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | NRAS, BRAF, MAP3K20 | HTR2C 4796/4885HTR2B 4225/4885HTR2A 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.